RTP Mobile Logo
Cancer Conference Update, Issue 1, 2011
Released March 2011

Featuring interviews with Drs Craig Moskowitz, Robert Z Orlowski, John P Leonard, Neil P Shah, Lauren C Pinter-Brown and Guillermo Garcia-Manero. (Audio Content)

CE Disclosures and Faculty Information


    Hematologic oncology is one of the most rapidly evolving fields in medicine. Results presented at major cancer conferences from a plethora of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing hematologist-oncologist must be well informed of these advances. To bridge the gap between research and patient care, this issue of Cancer Conference Update uses one-on-one discussions with Drs Moskowitz, Orlowski, Leonard, Shah, Pinter-Brown and Garcia-Manero to apply clinical trial data presented at the 2010 American Society of Hematology Annual Meeting in Orlando, Florida to the management of various types of hematologic cancer. This CME activity is thus designed to assist hematologist-oncologists with the formulation of up-to-date therapeutic algorithms for patients with lymphoid and myeloid cancer.


    • Apply emerging clinical trial data to the evidence-based selection of treatment for patients with 
hematologic cancer.
    • Develop evidence-based treatment algorithms for frequently encountered adult chronic leukemias.
    • Summarize emerging data with novel agents/combinations and radioimmunotherapy approaches for newly 
diagnosed or relapsed/refractory indolent or aggressive B-cell non-Hodgkin lymphomas.
    • Tailor up-front/induction therapy based on individual and disease characteristics for patients with multiple 
myeloma (MM).
    • Evaluate consolidation and maintenance therapy approaches for patients with MM.
    • Describe the standard therapeutic approaches and investigational strategies for the treatment of acute 
promyelocytic leukemia (APL).
    • Recall the efficacy and side effects of hypomethylating and immunomodulating agents in the treatment 
of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    • Describe therapeutic options for patients with peripheral and cutaneous T-cell lymphomas (PTCL and CTCL).


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should review the CME information and listen to the audio MP3s.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Garcia-Manero had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr MoskowitzAdvisory Committee: Cephalon Inc, Genentech BioOncology, Seattle Genetics; Paid Research: Cephalon Inc, Genentech BioOncology, Lilly USA LLC, Plexxikon Inc, Seattle Genetics. Dr OrlowskiSponsored Research Agreements: Celgene Corporation, Centocor Ortho Biotech Services LLC, Millennium — The Takeda Oncology Company. Dr LeonardConsulting Agreements: Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis. Dr ShahAdvisory Committee: ARIAD Pharmaceuticals Inc, Bristol-Myers Squibb Company. Dr Pinter-BrownAdvisory Committee: Allos Therapeutics, Celgene Corporation, Genentech BioOncology, Millennium — The Takeda Oncology Company; Consulting Agreement: Allos Therapeutics; Speakers Bureau: Genentech BioOncology.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Millennium — The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2011

    Expiration date: March 2012

Acknowledge and close

Listen to audio: